Los Angeles, California – January 13, 2020 – EntroGen, Inc. announces the immediate availability of its new NGS Targeted Hotspot Panel (THSP) designed to detect the most clinically relevant hotspot mutations in 16 genes across diverse tumor types.
Laboratories with relatively small sample volumes that process multiple tumor types are facing increasing challenges to find efficient and reliable testing options to streamline processing in order to save time and reduce cost. THSP addresses these challenges by offering end-users the ability to batch various sample types together on a single run while targeting specific, clinically relevant variants and maximizing utilization of NGS reagent cartridges.
The THSP kit is compatible with FFPE and fresh frozen samples. It features high sensitivity down to 5% with minimal DNA input and includes coverage for difficult to sequence regions in TERT and TP53 genes.
The panel is compatible with Illumina® MiniSeq, MiSeq and NexSeq 500. It includes reagents for target enrichment, library preparation and clean up, as well as user-friendly locally installed software designed to reduce the bioinformatics burden on the end-user by calling clinically relevant variants.
The company is obtaining a CE-IVD marking in the EU for the NGS Targeted Hotspot Panel. It is currently available worldwide for research use only.
Based in Los Angeles, California, EntroGen (http://www.entrogen.com) is a biotechnology company with a focus on molecular diagnostic products in the areas of hematology and oncology. EntroGen has a growing commercial portfolio with many of its products being used to guide and monitor targeted therapies for various malignancies. EntroGen’s footprint reaches every corner of the globe delivering reliable clinical and research products.
All trademarks and registered trademarks are the property of their respective owners.